scispace - formally typeset
B

Britt Mellström

Researcher at Karolinska Institutet

Publications -  25
Citations -  1873

Britt Mellström is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Nortriptyline & Debrisoquine. The author has an hindex of 18, co-authored 25 publications receiving 1868 citations. Previous affiliations of Britt Mellström include University of Bonn & University of Ghana.

Papers
More filters
Journal ArticleDOI

Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study.

TL;DR: There was a significant improvement in observed and self-reported obsessions and compulsions that was independent of the presence of depressive symptoms at baseline and the treatment seems to be independent of an antidepressant effect.
Journal ArticleDOI

Clomipramine Treatment of Obsessive-Compulsive Disorder: II. Biochemical Aspects

TL;DR: The amelioration of obsessive-compulsive symptoms was positively correlated to the reduction of CSF concentrations of 5-HIAA during clomipramine treatment but negatively correlated to plasma concentrations of clomIPramine.
Journal ArticleDOI

E- and Z-10-hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation

TL;DR: The strong correlation between the total plasma clearance of NT and the metabolic clearance by E‐10‐hydroxylation shows that this metabolic reaction is important in the disposition of the drug.
Journal ArticleDOI

Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression.

TL;DR: The biochemical and antidepressant effects of chlorimipramine (Cl) were studied in depressed patients after 3 wk of treatment as discussed by the authors, and the patients were subdivided into two groups, those with low and those with high CSF 5-HIAA.
Journal ArticleDOI

Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.

TL;DR: There was a close correlation between an individual's ability to hydroxylate debrisoquine and nortriptyline (measured as plasma clerance of the drug) and this indicates that these two benzylichydroxylations are controlled by similar if not identical genetic factors.